

Darin K Edwards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9595791/publications.pdf>

Version: 2024-02-01

15
papers

3,490
citations

687363

13
h-index

996975

15
g-index

29
all docs

29
docs citations

29
times ranked

5789
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	27.8	1,153
2	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1468-1470.	27.0	417
3	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 2025-2031.	30.7	361
4	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	27.0	338
5	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	12.6	244
6	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	28.9	179
7	Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2021, 95, e0131321.	3.4	89
8	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	12.6	83
9	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	28.9	71
10	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	28.9	64
11	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	3.8	63
12	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1042-1049.	30.7	61
13	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	14.5	57
14	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	12.4	13
15	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	5.5	7